[Therapeutic outcomes in systemic lymphatic diseases and plasmacytoma. New hope for palliative patients].
Heinrich
Bernhard
B
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis / Q000628:therapy*; D009101:Multiple Myeloma / Q000175:diagnosis / Q000628:therapy*; D011379:Prognosis; D011719:Pyrazines / Q000627:therapeutic use*; D016499:Radioimmunotherapy; D013792:Thalidomide / Q000627:therapeutic use*
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib